Amarin Corporation(AMRN) Newsfilter·2025-03-12 11:00Core Insights - Amarin Corporation reported a total revenue of $62.3 million for Q4 2024, a decrease of 17% compared to $74.7 million in Q4 2023, primarily due to lower net selling prices and reduced volume from U.S. generic competition [5][8][10] - The company ended 2024 with nearly $300 million in cash and no debt, reflecting a disciplined approach to capital management [2][5] - A 1-for-20 ADS ratio change was announced to maintain the company's Nasdaq listing, effective around April 11, 2025 [3][5] Financial Performance - Q4 2024 operating expenses were $43.0 million, down 18% from $49.7 million in Q4 2023 [5][12] - The net loss for Q4 2024 was $48.6 million, compared to a net loss of $5.8 million in Q4 2023, resulting in a basic and diluted loss per share of $0.12 [13][14] - Adjusted net loss for Q4 2024, excluding non-cash expenses, was $8.7 million, compared to an adjusted net loss of $0.9 million in Q4 2023 [14][35] Market Expansion and Product Performance - The company successfully launched VASCEPA/VAZKEPA in six additional global markets, including Italy, China, and Australia, and is progressing in 16 more countries [2][6] - In Italy, national reimbursement for VAZKEPA was secured, with access unlocked in over 50% of the eligible population [6] - U.S. net product revenue for Q4 2024 was $44.2 million, down from $64.9 million in Q4 2023, while European revenue increased to $4.0 million from $1.5 million [10][11] Research and Development - In 2024, Amarin's R&D team published 45 additional studies supporting the benefits of VASCEPA/VAZKEPA, enhancing the understanding of its cardiovascular risk reduction capabilities [7] - The company plans to present further data at the ACC.25 conference in March 2025, focusing on the antioxidant effects of EPA and its role in reducing cardiovascular events [9]